Proteomic profiling of ~5,000 proteins across heart failure subtypes in the EXSCEL trial reveals distinct biological pathways, with exenatide modifying some protein signatures.
~5,000 proteins analyzedComprehensive proteomic profiling revealed distinct biological pathways across heart failure ejection fraction subtypes
What the researchers found
Profiling ~5,000 proteins revealed distinct biological pathways across HFpEF, HFmrEF, and HFrEF in diabetic patients, with exenatide modifying some proteomic signatures.
Why it matters
Understanding the biological differences between heart failure subtypes could lead to subtype-specific treatments rather than one-size-fits-all approaches.
The numbers in context
1,199 participants with prevalent HF from EXSCEL trial. ~5,000 proteins profiled via SomaScan. Compared HFpEF (EF>55%), HFmrEF (40-55%), HFrEF (<40%). Baseline and 12-month samples.
How the study worked
Proteomic substudy of the EXSCEL randomized trial using SomaLogic SomaScan platform to measure ~5,000 proteins in baseline and 12-month samples from 1,199 participants with T2DM.
Who was studied
T2D patients with heart failure from the EXSCEL trial
What this study cannot tell us
Substudy of a trial not designed for heart failure as primary endpoint. Proteomic associations are observational and need functional validation.
How to read the evidence
Post hoc proteomic analysis of a major RCT — strong methodology but exploratory in nature. Findings need prospective validation.
When this study was published
Published in 2025, using state-of-the-art proteomics to characterize heart failure biology in the EXSCEL trial.
The bigger picture
This work supports precision medicine in heart failure — treating patients based on their specific disease biology rather than just ejection fraction numbers.
Questions still open
- Can proteomic profiles guide heart failure treatment selection?
- Do other GLP-1 drugs produce similar proteomic changes to exenatide?
Common questions
Are all types of heart failure the same?
Did the GLP-1 drug change heart failure biology?
Read the original research
Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.
Scientific reports, 15(1), 30170
Citation
Peters, Anthony E; Nguyen, Maggie; Green, Jennifer B; Pearson, Ewan R; Buse, John B; Sourij, Harald; Hernandez, Adrian F; Sattar, Naveed; Holman, Rury R; Mentz, Robert J; Shah, Svati H. (2025). Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.. Scientific reports, 15(1), 30170. https://doi.org/10.1038/s41598-025-14414-0